Welcome To IndiaHeartBeat.Com India's Leading Online Doctor Directory, Live Help

World's first medical networking and resource portal

Community Weblogs

Jan22

HIV /AIDS & HEPATITIS INFECTION : HEPATITIS C GENOTYPE IS NOT SERIOUS IN HIV-SO IF HEPATITIS IN HIV DONOT BE PANICKY

HIV /AIDS & HEPATITIS INFECTION : HEP C GENOTYPE IS NOT SERIOUS IN HIV

PROF.DRRAM ,HIV/AIDS,SEX DISEASES,SEX WEAKNESS & ABORTION SPECIALIST
profdrram@gmail.com,+917838059592,+919832025033 DELHI –NCR,INDIA
FOLLOW ON FACE BOOK:www.facebook.com/drramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
.
Hep C Genotype 3 Treatment Results Same in HIV Coinfection.
HIV INFECTION IN HEPATITIS B OR HEPATITIS C infection is mostly sen in blood contaminated or drug injectors as also reported in Northern USA too an outbreak of HEPATITIS B ,HEPATITIS C & HIV INFECTION seen where 26 patients become infected as Health Workers didnot change needles while taking blood samples .
As once HEPATITIS B or HEPATITIS C infection HIV infection is seen then it is very seious type of infection HIV treatment has to be started soon irrespective of CD4 COUNT or viral load study as both HEPATITIS AND HIV BECOME WORSE.
But in this study those who are coinfected with both HIV and genotype 3 of hepatitis C virus (HCV) responded about the same to interferon and ribavirin as those with only hep C in a recent Italian trial, aidsmap reports. Investigators conducted a retrospective analysis of 113 participants coinfected with HIV and hep C and 627 hep C monoinfected participants receiving treatment for hep C for the first time between 2005 and 2010. The scientists presented their findings at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Ninety-five percent of the coinfected participants had genotype 3 of hep C, while among the monoinfected group, 25 percent had genotype 2 and 55 percent genotype 3. Close to a quarter of the coinfected participants had advanced fibrosis or cirrhosis, compared with 5 percent of the monoinfected group.

In addition to ribavirin, two-thirds of the study participants received pegylated interferon alfa-2a and one-third received pegylated interferon alfa-2b. (Today's treatment involves pegylated interferon, ribavirin and one of two approved protease inhibitors; so this treatment paradigm is out of date.) All of the coinfected participants were treated for 48 weeks, while the monoinfected participants were permitted to stop treatment after 24 weeks if they either had no or moderate fibrosis, as well as a low hep C viral load at the outset and rapid virological response by the fourth week of treatment.

The coinfected group had an average sustained virologic response (SVR, considered a cure) of 58 percent, compared with an average SVR of 67 percent among the monoinfected participants.
This study is a landmark study as every hiv ptient will not be very serious if he develops HEPATITIS C INFECTION (4 photos)